Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methotrexate (ZENEO)
- Development stage
- Preclinical
- Lead developer
- Crossject
- Modality
- Small Molecules
- Administration
- Subcutaneous, Intramuscular
01
Overview
CJT-L9 is a needle-free autoinjector formulation of methotrexate, utilizing Crossject's proprietary ZENEO® technology. It is being developed for the treatment of chronic rheumatoid arthritis. Methotrexate is a well-established disease-modifying antirheumatic drug (DMARD) that functions as a folate analogue and inhibits dihydrofolate reductase (DHFR). This inhibition leads to a decrease in the synthesis of thymidylate and purines, thereby suppressing the proliferation of immune cells involved in the inflammatory process of rheumatoid arthritis. The ZENEO® device is designed to provide a needle-free, high-pressure injection, which may improve patient adherence and ease of administration compared to traditional needle-based syringes, especially for patients with limited hand dexterity or needle phobia.
- Other names
- Methotrexate
02
Targets
ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on Methotrexate (ZENEO).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Methotrexate (ZENEO).